Close Menu

Advanced Proteome Therapeutics and Atreus Pharmaceuticals have successfully site-specifically modified annexin V using a proprietary chemical approach, APT said this week.

As a result, various chemical entities can now be attached to the protein and thus enable the development of commercial products. The first such product currently under development is a conjugate of 1,4,7-traizacyclononane-1,4,7-triacetic acid, or NOTA, and recombinant human annexin V.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.